SpaceX Stock Finally Goes Public — and Joins the Nasdaq-100 in July
SpaceX stock (SPX) will join the Nasdaq-100 index on July 7, 2025. Learn what this means for index funds, retail investors, and the space economy.
SpaceX stock (SPX) will join the Nasdaq-100 index on July 7, 2025. Learn what this means for index funds, retail investors, and the space economy.
S&P 500, Nasdaq, and Dow futures surge as US and Iran de-escalate military strikes. Oil drops, tech rallies. What this means for your portfolio.
Oil prices rise 3% after US and Iran agree to suspend attacks in the Persian Gulf, but questions remain about IRGC compliance and market stability.
Comcast announces spin-off of NBCUniversal into a separate public company, ending a 14-year merger. What it means for investors, cable bills, and the media landscape.
Prime Inc. sues IRS for $11M over fuel tax credits on reefer diesel. The same credit small carriers can claim. Learn the tax implications and how to file.
Philippe Stern, who transformed Patek Philippe into a $40,000 status symbol and saved mechanical watchmaking, dies at 88. His legacy of scarcity and marketing redefined luxury.
Oil prices edge higher after three days of attacks in the Persian Gulf, but S&P 500 futures barely move. Why markets are calm — and why that could be dangerous.
A rogue builder took £30,000 for a roof repair, spent it on a Lanzarote holiday, and was ordered to pay back just £1. This is a brutal lesson in fraud and justice.
Wimbledon is back, but you don’t need a trust fund to play tennis. Here’s how to start with a $15 racket, free courts, and AI coaching that beats $100 lessons.
Dow futures slide as US-Iran airstrikes escalate, pushing markets to a tipping point. Tesla earnings and March jobs report loom. What investors need to know now.
DC Studios’ ‘Supergirl’ opens to just $38 million, trailing a horror film. With a $200M budget, the flop tests investor faith in the Gunn/Safran reboot strategy.
Starting July 1, Medicare Part D can cover obesity drugs like Wegovy and Zepbound for seniors. Yet most beneficiaries don’t know about this historic policy shift. We break down what changed, why drugmakers are silent, and what seniors should do now.